

# A patch test study of STS01 in healthy volunteers

<b>Submission date</b> 11/05/2022	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 08/08/2022	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 17/01/2025	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

In order to address the factors associated with poor tolerability and compliance with the administration of current preparations, the investigational medicinal product (IMP) will be a controlled release, cream-based, formulation STS01. The silicon atoms are 'activated' (electrically charged) to enable a controllable 'honeycomb' pore structure as a drug delivery mechanism with the potential to offer enhanced targeting and release characteristics. The main aim of this study is to look at whether a new controlled release formulation of STS01 has a beneficial effect on the skin irritation and skin staining potential that is seen with normal cream.

### Who can participate?

Healthy volunteers aged 18 – 70 years

### What does the study involve?

The study will comprise an initial open, prolonged exposure study (safety phase) to inform safety for the repeated application study (repeated phase). The safety phase is designed to determine the skin irritancy of each of the four topical formulations in healthy volunteer subjects, compared to the Base Formulation (with no dithranol) and E45 Dermatological Cream. The study will involve a progressive patch test with an increasing duration of exposure of up to 8 hours with follow-up assessments at 24, 48 and 72 hours. This approach is designed to minimise the exposure risk for the participants. Such an approach has been used previously to determine the irritancy of chemicals classified as irritants with no risk to participants. The repeat phase will be a double-blind, randomised study of the same set of creams, which will be applied to the lower back area of the participants. The creams will be applied to the test sites for periods of 1 hour on seven consecutive days with assessments on Days 1-13 and Day 16. Any clinical signs of cutaneous irritation (or any other clinical signs) will be recorded.

### What are the possible benefits and risks of participating?

This approach is designed to minimise the exposure risk for the participants. Such an approach has been used previously to determine the irritancy of chemicals classified as irritants with no risk to participants. Possible side effects from using other dithranol products include skin irritation and staining. The dithranol/ProSilic® cream formulation controls the drug release from the cream preparation and reduces this risk. Participants with an allergy likely to interfere with

the study are excluded. Participants will need to attend the Phase I unit clinic up to a maximum of four occasions. Participants who participated in the safety phase and had dithranol formulations applied to the skin may not participate in the repeated phase.

Where is the study run from?  
Soterios Ltd (UK)

When is the study starting and how long is it expected to run for?  
May 2022 to December 2022

Who is funding the study?  
Soterios Ltd (UK)

Who is the main contact?  
David Fleet  
davidfleet@manentia.co.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr David Fleet

**Contact details**  
Soterios Ltd  
East Grimstead  
Salisbury  
United Kingdom  
SP5 3RT  
+44 (0)1722 712972  
davidfleet@manentia.co.uk

**Type(s)**  
Principal investigator

**Contact name**  
Dr Stewart Long

**Contact details**  
Pendragon House  
Caxton Place  
Pentwyn  
Cardiff  
United Kingdom  
CF23 8XE  
+44 (0)2920 625686  
info@cutest.co.uk

# Additional identifiers

## Clinical Trials Information System (CTIS)

2022-001272-34

## Integrated Research Application System (IRAS)

1005742

## ClinicalTrials.gov (NCT)

Nil known

## Protocol serial number

AN3476/SOT03, IRAS 1005742

# Study information

## Scientific Title

A repeat open application patch test (ROAT) using a new controlled release formulation of STS01 cream in healthy volunteer subjects, preceded by a preliminary safety phase

## Study objectives

The primary objective is to investigate the irritancy and staining potential with a new controlled release formulation of STS01. The study will comprise an initial open, prolonged exposure study ("safety phase") to inform safety for the repeated application study ("repeated phase").

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 11/07/2022, Wales REC 1 (Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0)2920785738; wales.REC1@wales.mhs.uk), ref: 22/WA/0151

## Study design

Double-blind randomized placebo-controlled trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Healthy volunteer study - the treatment is for alopecia areata

## Interventions

Participants are randomised to a patch test of STS01 topical cream in strengths of 0.0%, 0.25%, 0.5%, 1% and 2% w/w or a control treatment (E45 Dermatological Cream); applied once.

## Intervention Type

Drug

**Phase**

Phase I

**Drug/device/biological/vaccine name(s)**

STS01

**Primary outcome(s)**

Assessment of test product contact with the skin using appropriate ranking scales, chromameter measurements and thermometry measurements. Staining of the application area will also be assessed by imaging (camera or TiVi Imaging System). Cream application sites will be assessed after a minimum of 10 minutes and a maximum of 30 minutes to allow any reactions due to the removal of the tape and test chamber to subside. The test chambers will be removed and assessed at 1, 2, 4 and 8 hours.

**Key secondary outcome(s)**

There are no secondary outcome measures

**Completion date**

31/12/2022

**Eligibility**

**Key inclusion criteria**

1. Subjects who are in the age range 18 – 70 years
2. Subjects with no significant concurrent illnesses or skin disease
3. Subjects who have signed the consent form after the nature of the study has been fully explained

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

70 years

**Sex**

All

**Total final enrolment**

59

## **Key exclusion criteria**

1. Pregnant or breastfeeding or lactating females or females who have given birth in the last 6 weeks
2. Subjects with a diagnosis of psoriasis, even if disease is not currently active
3. Subjects who participated in the safety phase and had dithranol formulations applied to the skin may not participate in the repeated phase
4. Subjects with atopy, self-diagnosed sensitive skin, or other dermatoses
5. Subjects who take any systemic or topical medication likely to interfere with the study e.g., anti-inflammatory drugs such as systemic steroids
6. Subjects who have taken part in a Health Research Authority or MHRA regulated clinical trial (e.g., at a hospital or Phase I unit) within the previous 8 weeks
7. Subjects who have taken part in a study involving the test site during the previous 4 weeks
8. Subjects with a recent history (previous 12 months) of significant skin disease requiring medical intervention, e.g., Dermatology outpatient appointment
9. Subjects with an allergy likely to interfere with the study
10. Subjects with a recent history of/ or evidence of alcohol, substance or drug abuse

## **Date of first enrolment**

09/06/2022

## **Date of final enrolment**

31/12/2022

## **Locations**

### **Countries of recruitment**

United Kingdom

Wales

### **Study participating centre**

**Cutest Systems Ltd**

Pendragon House

Caxton Place

Pentwyn

Cardiff

United Kingdom

CF23 8XE

## **Sponsor information**

### **Organisation**

Soterios Ltd

# Funder(s)

## Funder type

Industry

## Funder Name

Soterios Ltd

# Results and Publications

## Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

## IPD sharing plan summary

Data sharing statement to be made available at a later date

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>	version 1	23/12/2024	17/01/2025	No	No
<a href="#">HRA research summary</a>			28/06/2023	No	No